Nicholas Haft, Director at Finch Therapeutics Group, Inc. (FNCH), bought 63,850 shares at $10.18 ($650K) on 2021-12-20, disclosed to the SEC on 2021-12-22.
Open-market purchase of $650k FNCH by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Something here stands out, but not much.